Therapeutic efficacy of allogeneic hematopoietic stem cell transplantation in children with chronic myelogenous leukemia

JIANG Hua; HU Wen-Ting; CHEN Jing; LUO Chang-Ying; WANG Jian-Min; ZHOU Min; YE Qi-Dong; TANG Yan-Jing; LUO Cheng-Juan

doi:10.7499/j.issn.1008-8830.2013.01.006

PDF(961 KB)

Chinese Journal of Contemporary Pediatrics ›› 2013, Vol. 15 ›› Issue (1) : 19-24. DOI: 10.7499/j.issn.1008-8830.2013.01.006

CLINICAL RESEARCH

Therapeutic efficacy of allogeneic hematopoietic stem cell transplantation in children with chronic myelogenous leukemia

JIANG Hua, HU Wen-Ting, CHEN Jing, LUO Chang-Ying, WANG Jian-Min, ZHOU Min, YE Qi-Dong, TANG Yan-Jing, LUO Cheng-Juan

Author information +

History +

Abstract

OBJECTIVE: To investigate the therapeutic efficacy of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in children with chronic myelogenous leukemia (CML), and to analyze the possible prognostic factors.MethodsThe clinical data of 20 children with CML who had received allo-HSCT was analyzed retrospectively to investigate possible prognostic factors, including age, sex, interval between diagnosis and transplantation, HLA matching between donors and recipients, illness status on transplantation and acute and chronic graft-versus-host disease (GVHD).ResultsAt the end of follow-up, 13 of the 20 treated children had disease-free survival (DFS) and the rest (7 cases) died. Four died of severe acute GVHD, two of chronic GVHD and its complications, and one of relapse after transplantation. The three-year DFS was (64.6±1.1%). As shown by the univariate analysis, age was the most important prognostic factor in children with CML who had received allo-HSCT (P<0.05), and in children over 10 years, the prognosis was poor. No other of the above factors had a significant impact on prognosis (P>0.05). The multivariate logistic regression analysis also confirmed age as the only prognostic factor (P<0.01). Severe acute and/or chronic GVHD was the most important cause of patient death. 10/10 HLA-matched donors could improve the transplantation outcome.ConclusionsAllo-HSCT is an effective treatment for children with CML. To improve the prognosis and treatment outcome, children with CML aged over 10 years should receive allo-HSCT as early as possible. 10/10 HLA-matched donors are preferred in allo-HSCT and GVHD should be prevented.

Key words

Chronic myelogenous leukemia / Allogeneic hematopoietic stem cell transplantation / Graft-versus-host disease / Child

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

JIANG Hua, HU Wen-Ting, CHEN Jing, LUO Chang-Ying, WANG Jian-Min, ZHOU Min, YE Qi-Dong, TANG Yan-Jing, LUO Cheng-Juan. Therapeutic efficacy of allogeneic hematopoietic stem cell transplantation in children with chronic myelogenous leukemia[J]. Chinese Journal of Contemporary Pediatrics. 2013, 15(1): 19-24 https://doi.org/10.7499/j.issn.1008-8830.2013.01.006

References

［1］Castro-Malaspina H, Schaison G, Briere J, Passe S, Briere J, Pasquier A, et al. Philadelphia chromosome-positive chronic myelocytic leukemia in children. Survival and prognostic factors［J］. Cancer, 1983, 52(4): 721-727.

［2］Altman AJ. Chronic leukemias of childhood［J］. Pediatr Clin North Am, 1988, 35(4): 765-787.

［3］Lee JW, Chung NG. The treatment of pediatric chronic myelogenous leukemia in the imatinib era［J］. Korean J Pediatr, 2011, 54(3): 111-116.

［4］Sokal JE, Baccarani M, Russo D, Tura S. Staging and prognosis in chronic myelogenous leukemia［J］. Semin Hematol, 1988, 25(1): 49-61.

［5］韩伟，陆道培，黄晓军，刘开彦，陈欢，许兰平，等.HLA配型不合造血干细胞移植GIAC方案100例临床分析［J］. 中华血液学杂志，2004，25（8）：453-457.

［6］Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. 1994 consensus conference on acute GVHD grading［J］. Bone Marrow Transplant, 1995, 15(6): 825-828.

［7］Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report［J］. Biol Blood Marrow Transplant, 2005, 11(12): 945-956.

［8］Goldman JM, Szydlo R, Horowitz MM, Gale RP, Ash RC, Atkinson K, et al. Choice of pretreatment treatment and timing of transplants for chronic myelogenous leukemia in chronic phase［J］. Blood, 1993, 82(7): 2235-2238.

［9］Gratwohl A, Hermans J, Apperley J, Arcese W, Bacigalupo A, Bandini G, et al. Acute graft-versus-host disease: grade and outcome in patients with chronic myelogenous leukemia［J］. Blood, 1995, 86(2): 813-818.

［10］Sharathkumar A, Thornley I, Saunders EF, Calderwood S, Freedman MH, Doyle J. Allogenic bone marrow transplantation in children with chronic myelogenous leukemia［J］. J Pediatr Hematol Oncol, 2002, 24(3): 215-219.

［11］Thomas ED, Clift RA, Fefer A, Appelbaum FR, Beatty P, Bensinger WI, et al. Marrow transplantation for the treatment of chonic myelogenous leukemia［J］. Ann Intern Med, 1986, 104(2): 155-163.

［12］Gratwohl A, Brand R, Apperley J, Crawley C, Ruutu T, Corradini P, et al. Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, longterm data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT) ［J］. Haematologica, 2006, 91(4): 513-521.

［13］Unal S, Fidan G, Tavil B, Cetin M, Cetinkaya DU. Allogeneic hematopoietic stem cell transplantation in pediatric chronic myelogenous leukemia cases: Hacettepe experience［J］. Pediatr Transplant, 2007, 11(6): 645-649.

［14］Cwynarski K, Roberts IA, Iacobelli S, van Biezen A, Brand R, Devergie A, et al. Stem cell transplantation for chronic myeloid leukemia in children［J］. Blood, 2003, 102(4): 1224-1231.

［15］Rubio MT, Moreira-Teixeira L, Bachy E, Bouillié M, Milpied P, Coman T,et al.Early posttransplantation donor-derived invariant natural killer T-cell recovery predicts the occurrence of acute graft-versus-host disease and overall survival［J］. Blood, 2012, 120(10): 2144-2154.

［16］Suttorp M, Yaniv I, Schultz KR.Controversies in the treatment of CML in children and adolescents: TKIs versus BMT?［J］. Biol Blood Marrow Transplant, 2011, 17(1 Suppl): S115-S122.